entertainment
A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
advertisement
Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Cassava Sciences’ Alzheimer’s clinical trials should be halted
Next article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Tori Bowie and the unacceptable rates of Black maternal death
